TFX

As of 2026-09-10, TFX scores 44out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. TFX trades at $132.00, 11% below the band floor.

TFX scores 44 out of 100 on QNTM's five-factor model — a low-conviction reading — at 44 the factor profile is among the weaker names in the universe. Its strongest factor is value at 73 (strong), where it screens cheap on the model's valuation inputs, followed by momentum at 46. The weakest is sentiment at 20, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 43% of Healthcare names by composite.

On valuation, TFX is priced near the floor of its own recent range — the cheap end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 46. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on TFX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where TFX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for TFX runs $148.21–$214.53. Current price $132.00 sits 11% below the band floor. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.